EASO Position Statement: Women with Obesity across the Reproductive Life – Fertility, Preconception, Pregnancy, Postpartum, and Breastfeeding
Obesity Facts · 21.06.2025 · 18 (6) · 625-639
DOI: 10.1159/000546449 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Obesity Facts, online erschienen am 21.06.2025. Verfasst von Francesca Filippi-Arriaga und 7 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology and Nutrition Department, Obesity Unit, Vall Hebron University Hospital, Barcelona, Spain, francesca.filippi@vhir.org. Hauptthemen laut MEDLINE: Obesity, Breast Feeding, Fertility, Pregnancy Complications. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Hebammenwesen und Geburtshilfe, Stillen
Abstract (Originalsprache)
Background: Obesity management in women presents distinct challenges across their lifespan. However, there is limited evidence or recommendations focused solely on women living with obesity. Summary: This European Association for the Study of Obesity (EASO) position statement is based on an expert comprehensive review and summary of the available scientific evidence on women living with obesity. It aims to guide the health and medical assessment of these women during their reproductive life (fertility, preconception, pregnancy, postpartum, and breastfeeding). Key Messages: 1. To better diagnose obesity in women beyond BMI, the use of at least one additional anthropometric measure, like waist-to-height ratio (WHtR), is strongly recommended. When available, the use of bioelectrical impedance vector analysis is encouraged. 2. Women with obesity should be offered obesity management counseling and psychological support. 3. Obesity can negatively impact fertility; weight loss of 5–10% over 6 months improves fertility. 4. In women with Polycystic Ovary Syndrome (PCOS), treatment with metformin and GLP-1 receptor agonists or surgery can be considered. 5. Current recommendations for pregestational obesity suggest a gestational weight gain (GWG) of 5–9 kg. Lower GWG targets should be considered, particularly for class II or III obesity. 6. There is limited clinical data on the safety and efficacy of obesity medication during pregnancy or lactation. 7. All pregnant women with obesity should be offered prenatal screening for fetal anomalies, with discussion of the potential limitations of diagnostic tests and additional growth ultrasounds offered on an individual basis. 8. All pregnant women with a BMI ≥30 kg/m2 should be screened for gestational diabetes in early pregnancy. Measures to prevent preeclampsia should be taken and the need for thromboprophylaxis assessed. 9. Intrapartum fetal surveillance is recommended during active labor. 10. Postpartum weight management is needed to mitigate the risk of adverse outcomes for the mother and for subsequent pregnancies. The assessment of appropriate contraceptive methods during the postpartum and breastfeeding period is crucial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Endocrinology and Nutrition Department, Obesity Unit, Vall Hebron University Hospital, Barcelona, Spain, francesca.filippi@vhir.org.
- Endocrinology, Obesity and Bariatric Department, Imperial College London Diabetes Centre, Abu Dhabi, United Arab Emirates.
- Department of Obstetrics, Centro Materno-Infantil do Norte Dr. Albino Aroso (CMIN), Unidade Local de Saúde de Santo António (ULSSA), Porto, Portugal.
- Endocrine and Metabolic Research, Unit for Multidisciplinary Research in Biomedicine (UMIB), School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal.
- Laboratory for Integrative and Translational Research in Population Health (ITR), University of Porto, Porto, Portugal.
- Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Zitieren
APA
Filippi-Arriaga, F., Agarwal, N., Rodrigues-Martins, D., Monteiro, M. P., Huvinen, E., Suliman, S. G. I., McGowan, B., & Ciudin, A. (2025). EASO Position Statement: Women with Obesity across the Reproductive Life – Fertility, Preconception, Pregnancy, Postpartum, and Breastfeeding. Obesity Facts, 18(6), 625-639. https://doi.org/10.1159/000546449
Vancouver
Filippi-Arriaga F, Agarwal N, Rodrigues-Martins D, Monteiro MP, Huvinen E, Suliman SGI, et al. EASO Position Statement: Women with Obesity across the Reproductive Life – Fertility, Preconception, Pregnancy, Postpartum, and Breastfeeding. Obesity Facts. 2025;18(6):625-639. doi:10.1159/000546449
BibTeX
@article{FilippiArriaga2025,
author = {Filippi-Arriaga, Francesca and Agarwal, Nidhi and Rodrigues-Martins, Diana and Monteiro, Mariana P and Huvinen, Emilia and Suliman, Sara G I and McGowan, Barbara and Ciudin, Andreea},
title = {EASO Position Statement: Women with Obesity across the Reproductive Life – Fertility, Preconception, Pregnancy, Postpartum, and Breastfeeding},
journal = {Obesity Facts},
year = {2025},
volume = {18},
number = {6},
pages = {625--639},
doi = {10.1159/000546449}
}
EUVIMED